sorbitol has been researched along with Leishmaniasis in 12 studies
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).
Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-six Guatemalans with parasitologically proven cutaneous leishmaniasis were randomly and equally divided into 3 treatment groups: those receiving meglumine antimonate (Glucantime), 850 mg antimony/day im for 15 days; those receiving localized controlled heat from a radio-frequency generator, 50 degrees C for 30 sec, 3 treatments at 7 day intervals; and those receiving treatment with a placebo." | 9.06 | Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. ( Arana, BA; Arana, FE; Castillo, AL; de Mérida, AM; Navin, TR; Pozuelos, JL, 1990) |
| "Sixty-six Guatemalans with parasitologically proven cutaneous leishmaniasis were randomly and equally divided into 3 treatment groups: those receiving meglumine antimonate (Glucantime), 850 mg antimony/day im for 15 days; those receiving localized controlled heat from a radio-frequency generator, 50 degrees C for 30 sec, 3 treatments at 7 day intervals; and those receiving treatment with a placebo." | 5.06 | Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. ( Arana, BA; Arana, FE; Castillo, AL; de Mérida, AM; Navin, TR; Pozuelos, JL, 1990) |
| "Chlorpromazine (CPZ) was effective in vitro against leishmanial promastigotes and amastigotes." | 1.27 | In vitro and in vivo anti-leishmanial activity of chlorpromazine alone and combined with N-meglumine antimonate. ( el-On, J; Kernbaum, S; Rubinstein, N; Schnur, LF, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (75.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avila, JL | 1 |
| Biondo, F | 1 |
| Monzón, H | 1 |
| Convit, J | 2 |
| Alving, CR | 1 |
| Steck, EA | 1 |
| Hanson, WL | 1 |
| Loizeaux, PS | 1 |
| Chapman, WL | 1 |
| Waits, VB | 1 |
| Rzany, B | 1 |
| Krutmann, J | 1 |
| Goerttler, E | 1 |
| Schöpf, E | 1 |
| Dorea, JG | 1 |
| Merchan-Hamann, E | 1 |
| Ryan, DE | 1 |
| Holzbecher, J | 1 |
| Navin, TR | 1 |
| Arana, BA | 1 |
| Arana, FE | 1 |
| de Mérida, AM | 1 |
| Castillo, AL | 1 |
| Pozuelos, JL | 1 |
| Jackson, JE | 1 |
| Tally, JD | 1 |
| Tang, DB | 1 |
| Sáenz, RE | 1 |
| Paz, HM | 1 |
| Johnson, CM | 1 |
| Narvaez, E | 1 |
| de Vásquez, AM | 1 |
| Castellanos, PL | 1 |
| Rondon, A | 1 |
| Pinardi, ME | 1 |
| Ulrich, M | 1 |
| Castes, M | 1 |
| Bloom, B | 1 |
| Garcia, L | 1 |
| Kumar, PV | 1 |
| Sadeghi, E | 1 |
| Torabi, S | 1 |
| el-On, J | 1 |
| Rubinstein, N | 1 |
| Kernbaum, S | 1 |
| Schnur, LF | 1 |
| Kurban, A | 1 |
| Addadi, K | 1 |
| Hamladji, MR | 1 |
| Tabet-Derraz, O | 1 |
| Abbadi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
2 trials available for sorbitol and Leishmaniasis
| Article | Year |
|---|---|
Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala.
Topics: Adult; Animals; Antimony; Antiprotozoal Agents; Follow-Up Studies; Guatemala; Hot Temperature; Human | 1990 |
Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis.
Topics: Adolescent; Adult; Antibodies; Antigens, Protozoan; Antiprotozoal Agents; Child; Clinical Trials as | 1987 |
10 other studies available for sorbitol and Leishmaniasis
| Article | Year |
|---|---|
Cutaneous leishmaniasis in mice: resistance to glucan immunotherapy, either alone or combined with chemotherapy.
Topics: Animals; Antimony; Dose-Response Relationship, Immunologic; Female; Glucans; Immunotherapy; Leishman | 1982 |
Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug.
Topics: Animals; Cricetinae; Leishmaniasis; Liposomes; Meglumine; Mesocricetus; Sorbitol; Time Factors | 1978 |
[Cutaneous leishmaniasis: treatment with cryotherapy and intramuscular injections of meglumine antimonate (glucantime)].
Topics: Adult; Combined Modality Therapy; Cryosurgery; Female; Humans; Injections, Intramuscular; Leishmania | 1990 |
Retention of antimony in skin biopsies of leishmaniasis patients after treatment with N-methylglucamine antimoniate.
Topics: Adolescent; Adult; Aged; Antimony; Biopsy; Child; Double-Blind Method; Drug Administration Schedule; | 1990 |
An in vitro micromethod for drug sensitivity testing of Leishmania.
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Culture Media; Gluconates; Human | 1989 |
[Evaluation of the effectiveness and toxicity of pentostam and glucantime in the treatment of cutaneous leishmaniasis].
Topics: Adult; Antimony Sodium Gluconate; Drug Evaluation; Female; Gluconates; Humans; Immunologic Technique | 1987 |
Kala azar with disseminated dermal leishmaniasis.
Topics: Adolescent; Antiprotozoal Agents; Biopsy; Child; Female; Humans; Iran; Leishmaniasis; Leishmaniasis, | 1989 |
In vitro and in vivo anti-leishmanial activity of chlorpromazine alone and combined with N-meglumine antimonate.
Topics: Animals; Antiprotozoal Agents; Chlorpromazine; Drug Therapy, Combination; Leishmania; Leishmaniasis; | 1986 |
[What did prove useful in the treatment of leishmaniasis].
Topics: Antimony; Humans; Leishmaniasis; Sorbitol | 1973 |
[Protozoa "incertae sedis" or particular forms of Leishmania?].
Topics: Adult; Amino Sugars; Anemia; Antibodies; Antimony; Antiprotozoal Agents; Bone Marrow; Female; Fever; | 1971 |